PatentJul 13, 2026, 08:02 AM
Madrigal Pharmaceuticals Secures 3 New Rezdiffra Patents
AI Summary
Madrigal Pharmaceuticals announced the issuance of three new U.S. patents for its drug Rezdiffra (resmetirom). Two of these patents strengthen protection for the F2/F3 MASH indication, with one extending to 2045 and another to 2042, and will be listed in the FDA's Orange Book. The third patent covers a method of administering resmetirom for well-compensated cirrhosis (F4c) and provides protection until 2042, reinforcing the company's long-term intellectual property strategy.
Key Highlights
- Madrigal Pharmaceuticals received three new U.S. patents for Rezdiffra (resmetirom).
- Two patents reinforce protection for F2/F3 MASH treatment.
- One patent supports the potential F4c (well-compensated cirrhosis) indication.
- U.S. Patent No. 12,667,575 (F2/F3) provides protection until 2045.
- U.S. Patent No. 12,661,359 (F2/F3) provides protection until 2042.
- U.S. Patent No. 12,661,361 (F4c) provides protection until 2042.
- Two F2/F3 patents will be listed in the FDA’s Orange Book.
Price Impact
More from MDGL